冬青素B | 13849-91-7

• 物质功能分类: 天然产物 - 萜类
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 冬青素B
• 英文名称: pomolic acid
• 英文别名: (1R,2R,4aS,6aR,6aS,6bR,10S,12aR,14bS)-1,10-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
• CAS: 13849-91-7；19870-71-4；109008-39-1；119067-01-5
• 化学式: C₃₀H₄₈O₄
• 分子量: 472.709
• InChiKey: ZZTYPLSBNNGEIS-LBZDZBPWSA-N

物化性质

• 熔点：
  297-299 °C(Solv: chloroform (67-66-3); methanol (67-56-1))
• 沸点：
  586.2±50.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)
• 溶解度：
  溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  34
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• WGK Germany：
  3

制备方法与用途

生物活性

Randialic acid A（Pomolic acid）是一种五环三萜烯，是从Euscaphis japonica中分离出来的。研究表明，Randialic acid A能够抑制肿瘤细胞的生长并诱导细胞凋亡，显示出在前列腺癌治疗中的潜力。

靶点

• IC50: apoptosis

体外研究

Randialic acid A（Pomolic acid）能诱导胶质母细胞瘤（GBM）细胞发生凋亡，这通过DNA片段化得以验证。Pomolic酸引发的凋亡过程依赖于活性氧物种（ROS）的产生。此外，它还能导致线粒体膜电位解耦合，并激活caspase-3和caspase-9。

反应信息

• 作为反应物：
  描述：

  冬青素B 、 乙酸酐 、 吡啶 生成 (1R,2R,4aS,6aR,6aS,6bR,10S,12aR,14bS)-1,10-diacetyloxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
  参考文献：
  名称：

  ISOBE, TAKAHIKO;NODA, YUKINAO;OHSAKI, AYUMI;SAKANAKA, SENJI;KIM, MUJO;TAN+, YAKUGAKU DZASSI, 109,(1989) N, S. 175-176

  摘要：

  DOI：

文献信息

• USE OF URSOLIC ACID SAPONIN,OLEANOLIC ACID SAPONIN IN PREPARATION OF INCREASING LEUCOCYTES AND/OR PLATELET MEDICINE
  申请人：Guang Bing

  公开号：US20100197898A1

  公开（公告）日：2010-08-05

  The invention provides the use of ursolic acid saponin and oleanolic acid saponin of formula (I) in preparing medicaments for increasing leucocytes and/or platelets. The invention also provides a pharmaceutical composition containing the same compound. The invention utilizes the cheap and accessible ursolic acid and oleanolic acid which are widely present in natural plants as raw materials, introduces monosaccharyls or oligosaccharyls by structural modification. It is proved by pharmacological tests that the compound of formula (I) have an activity of obviously increasing leucocytes and/or platelets.

  本发明提供了使用式(I)的熊果酸皂苷和齐墩果酸皂苷制备增加白细胞和/或血小板的药物的方法。本发明还提供了含有相同化合物的制药组合物。本发明利用廉价且易得的熊果酸和齐墩果酸，它们广泛存在于天然植物中作为原料，并通过结构修饰引入单糖或寡糖。药理学试验证明，式(I)化合物具有明显增加白细胞和/或血小板的活性。
• Cyclopropane amines
  申请人：AstraZeneca AB

  公开号：EP1386909A1

  公开（公告）日：2004-02-04

  The invention provides a compound of formula (III): where R2 is a phenyl group, optionally substituted by one or more fluorine atoms, or is a protected derivative thereof..

  本发明提供了一种式 (III) 的化合物： 其中 R2 是任选被一个或多个氟原子取代的苯基，或者是其受保护的衍生物。
• Intermediates
  申请人：AstraZeneca AB

  公开号：EP1386921A1

  公开（公告）日：2004-02-04

  The invention provides the compounds: (1S-cis)-2-[[4-[[6-Chloro-5-nitro-2-[(3,3,3-trifluoropropyl)thio]-4-pyrimidinyl]amino]-2-cyclopenten-1-yl]oxy]-acetic acid, ethyl ester; [3aS-(3aα,4α,6α,6aα)]-[Tetrahydro-6-hydroxy-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]-carbamic acid, phenylmethyl ester; [3aS-(3aα,4α,6α,6aα)]-[2,2-Dimethyl-6-(2-hydroxyethoxy)-tetrahydro-4H-cyclopenta-1,3-dioxol-4-yl]-carbamic acid, phenylmethyl ester; [3aR-(3aα,4α,6α,6aα)]-2-[[6-Amino-2,2-dimethyl-tetrahydro-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-ethanol; 2-(Butylthio)-4,6-dichloropyrimidine-5-amine; [3aR-(3aα,4α,6α,6aα)]-2-[[6-[[5-Amino-2-(butylthio)-6-chloro-pyrimidin-4-yl]amino]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]ethanol; [3aR-(3aα,4α,6α,6aα)]-6-[[6-Chloro-5-nitro-2-(propylthio)-pyrimidin-4-yl]amino]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol.

  本发明提供了这些化合物： (1S-cis)-2-[[4-[[6-Chloro-5-nitro-2-[(3,3,3-trifluoropropyl)thio]-4-pyrimidinyl]amino]-2-cyclopenten-1-yl]oxy]-acetic acid, ethyl ester; [3aS-(3aα,4α,6α,6aα)]-[四氢-6-羟基-2,2-二甲基-4H-环戊烯-1,3-二氧戊环-4-基]-氨基甲酸苯甲酯； [3aS-(3aα,4α,6α,6aα)]-[2,2-二甲基-6-(2-羟基乙氧基)-四氢-4H-环戊-1,3-二氧戊环-4-基]-氨基甲酸苯甲酯； [3aR-(3aα,4α,6α,6aα)]-2-[[6-Amino-2,2-dimethyl-tetrahydro-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-ethanol; 2-(丁硫基)-4,6-二氯嘧啶-5-胺； [3aR-(3aα,4α,6α,6aα)]-2-[[6-[[5-Amino-2-(butylthio)-6-chloro-pyrimidin-4-yl]amino]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]ethanol; [3aR-(3aα,4α,6α,6aα)]-6-[[6-Chloro-5-nitro-2-(propylthio)-pyrimidin-4-yl]amino]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol.
• Compositions that treat or inhibit pathological conditions associated with inflammatory response
  申请人：Metaproteomics, LLC

  公开号：EP2221052A2

  公开（公告）日：2010-08-25

  The present invention relates to the use of a composition comprising an effective amount of a compound selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-isoadhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-isoadhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-isoadhumulone, in the manufacture of a therapeutic composition for treating or preventing inflammatory or inflammation-associated disorders.

  本发明涉及一种组合物的用途，该组合物含有有效量的选自以下组别的化合物：二氢-异胡麻酮、二氢-异胡麻酮、二氢-异胡麻酮、四氢-异胡麻酮、四氢-异胡麻酮、六氢-异胡麻酮、六氢-异胡麻酮和六氢-异胡麻酮、四氢-异胡芦巴内酯、四氢-异胡芦巴内酯、六氢-异胡芦巴内酯、六氢-异胡芦巴内酯和六氢-异胡芦巴内酯。
• Composition of curcumagalactomannoside and hops extract
  申请人：Metagenics, Inc.

  公开号：US11026897B2

  公开（公告）日：2021-06-08

  A composition for treatment of inflammation in a mammal is provided. The mammal has a neutrophil to lymphocyte ratio (NLR). The composition includes a curcumagalactomannoside and a hops extract. The curcumagalactomannoside and the hops extract cooperate to decrease the NLR of the mammal 12 weeks after ingestion of the composition. A method of treatment of inflammation in a mammal is also provided. The method includes obtaining a parameter of the mammal. The method further includes dosing the composition based on the parameter. The method further includes administering the composition to the mammal.

  提供了一种用于治疗哺乳动物炎症的组合物。哺乳动物的中性粒细胞与淋巴细胞比率（NLR）。该组合物包括姜黄半乳甘露糖苷和啤酒花提取物。姜黄半乳甘露糖苷和啤酒花提取物可在哺乳动物摄入组合物 12 周后协同降低其 NLR。还提供了一种治疗哺乳动物炎症的方法。该方法包括获得哺乳动物的参数。该方法还包括根据参数给组合物配料。该方法还包括向哺乳动物施用组合物。